Literature DB >> 16118809

One- and two-stage designs for stratified phase II clinical trials.

Wendy B London1, Myron N Chang.   

Abstract

A global one-sample test for response rates for stratified phase II clinical trials is proposed. Such a test is analogous to that of a stratified log-rank test for time-to-event data. Both one- and two-stage tests are developed, and conditional and unconditional approaches are introduced in each case, where the conditional approach involves conditioning on the observed samples sizes within the strata. The methodology generates samples sizes and stopping boundaries that provide designs with the desired power and type I error probability. These methods are useful for designing stratified phase II clinical trials. An application to a Children's Oncology Group phase II clinical trial in relapsed neuroblastoma patients is presented. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118809     DOI: 10.1002/sim.2139

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  17 in total

1.  Phase II Trials for Heterogeneous Patient Populations with a Time-to-Event Endpoint.

Authors:  Sin-Ho Jung
Journal:  Med Res Arch       Date:  2017-07-15

2.  Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.

Authors:  Gini F Fleming; Virginia L Filiaci; Brandon Marzullo; Richard J Zaino; Susan A Davidson; Michael Pearl; Vicky Makker; James J Burke; Susan L Zweizig; Linda Van Le; Parviz Hanjani; Gordon Downey; Joan L Walker; Henry D Reyes; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2014-01-20       Impact factor: 5.482

3.  Improved two-stage tests for stratified phase II cancer clinical trials.

Authors:  Myron N Chang; Jonathan J Shuster; Wei Hou
Journal:  Stat Med       Date:  2012-03-16       Impact factor: 2.373

4.  An efficient basket trial design.

Authors:  Kristen M Cunanan; Alexia Iasonos; Ronglai Shen; Colin B Begg; Mithat Gönen
Journal:  Stat Med       Date:  2017-01-18       Impact factor: 2.373

5.  Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.

Authors:  Hui Tang; Nathan R Foster; Axel Grothey; Stephen M Ansell; Richard M Goldberg; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

6.  Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.

Authors:  Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Xiaomin Lu; Meenakshi Devidas; Joel M Reid; David M Goldenberg; William A Wegener; Hui Zeng; James A Whitlock; Peter C Adamson; Stephen P Hunger; William L Carroll
Journal:  Pediatr Blood Cancer       Date:  2015-03-02       Impact factor: 3.167

Review 7.  Bayesian designs to account for patient heterogeneity in phase II clinical trials.

Authors:  Peter F Thall; J Kyle Wathen
Journal:  Curr Opin Oncol       Date:  2008-07       Impact factor: 3.645

8.  Proper inference from Simon's two-stage designs.

Authors:  Tatsuki Koyama; Heidi Chen
Journal:  Stat Med       Date:  2008-07-20       Impact factor: 2.373

Review 9.  Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.

Authors:  Anastasia Ivanova; Barry Paul; Olga Marchenko; Guochen Song; Neerali Patel; Stergios J Moschos
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

10.  Accounting for patient heterogeneity in phase II clinical trials.

Authors:  J Kyle Wathen; Peter F Thall; John D Cook; Elihu H Estey
Journal:  Stat Med       Date:  2008-07-10       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.